Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
2.370
+0.130 (5.80%)
Dec 3, 2024, 9:48 AM EST - Market open
Lexaria Bioscience Income Statement
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Aug '24 Aug 31, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | 2019 - 2015 |
| Revenue | 0.46 | 0.46 | 0.23 | 0.26 | 0.72 | 0.31 | Upgrade
|
| Revenue Growth (YoY) | 105.24% | 105.24% | -11.43% | -64.66% | 129.59% | 41.41% | Upgrade
|
| Cost of Revenue | 0 | 0 | 0.03 | 0.07 | 0.18 | 0.1 | Upgrade
|
| Gross Profit | 0.46 | 0.46 | 0.19 | 0.18 | 0.55 | 0.22 | Upgrade
|
| Selling, General & Admin | 3.79 | 3.79 | 2.96 | 4.96 | 4.97 | 3.98 | Upgrade
|
| Research & Development | 2.36 | 2.36 | 3.67 | 1.84 | 1.26 | 0.39 | Upgrade
|
| Operating Expenses | 6.15 | 6.15 | 6.62 | 6.8 | 6.23 | 4.36 | Upgrade
|
| Operating Income | -5.7 | -5.7 | -6.43 | -6.62 | -5.69 | -4.15 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.04 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -5.68 | -5.68 | -6.38 | -6.62 | -5.69 | -4.15 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.07 | -0.07 | -0.22 | -0.76 | - | - | Upgrade
|
| Asset Writedown | -0.06 | -0.06 | -0.11 | - | - | - | Upgrade
|
| Pretax Income | -5.81 | -5.81 | -6.71 | -7.38 | -5.69 | -4.15 | Upgrade
|
| Earnings From Continuing Operations | -5.81 | -5.81 | -6.71 | -7.38 | -5.69 | -4.15 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 1.5 | 0.06 | Upgrade
|
| Net Income to Company | -5.81 | -5.81 | -6.71 | -7.38 | -4.19 | -4.08 | Upgrade
|
| Minority Interest in Earnings | 0.01 | 0.01 | 0.05 | 0.11 | 0.16 | 0.15 | Upgrade
|
| Net Income | -5.8 | -5.8 | -6.66 | -7.27 | -4.03 | -3.93 | Upgrade
|
| Net Income to Common | -5.8 | -5.8 | -6.66 | -7.27 | -4.03 | -3.93 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 7 | 6 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 7 | 6 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | 87.24% | 87.24% | 12.38% | 34.02% | 58.34% | 6.95% | Upgrade
|
| EPS (Basic) | -0.47 | -0.47 | -1.01 | -1.24 | -0.92 | -1.42 | Upgrade
|
| EPS (Diluted) | -0.47 | -0.47 | -1.01 | -1.24 | -0.92 | -1.42 | Upgrade
|
| Free Cash Flow | -5 | -5 | -5.91 | -4.93 | -3.99 | -2.62 | Upgrade
|
| Free Cash Flow Per Share | -0.40 | -0.40 | -0.89 | -0.84 | -0.91 | -0.94 | Upgrade
|
| Gross Margin | 98.96% | 98.96% | 86.07% | 71.87% | 75.74% | 68.43% | Upgrade
|
| Operating Margin | -1226.70% | -1226.70% | -2841.31% | -2591.67% | -786.85% | -1317.94% | Upgrade
|
| Profit Margin | -1248.25% | -1248.25% | -2946.36% | -2846.28% | -557.19% | -1249.71% | Upgrade
|
| Free Cash Flow Margin | -1077.38% | -1077.38% | -2614.84% | -1929.75% | -552.02% | -831.91% | Upgrade
|
| EBITDA | -5.62 | -5.62 | -6.28 | -6.52 | -5.58 | -4.04 | Upgrade
|
| D&A For EBITDA | 0.08 | 0.08 | 0.15 | 0.1 | 0.11 | 0.11 | Upgrade
|
| EBIT | -5.7 | -5.7 | -6.43 | -6.62 | -5.69 | -4.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.